Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

AJAndrew JalloukSKSwetha KambhampatiSBShakthi Bhaskar

Discussion

Loading...

Member takes

Overview

Observational analysis reveals high response rates with mosunetuzumab in B-cell lymphomas, suggesting efficacy in diverse lymphoma subtypes.

Key Points

  • Mosunetuzumab demonstrated a complete response in 71% of patients with indolent lymphomas and 67% in aggressive lymphomas, indicating effective treatment.
  • Survival analysis showed a median progression-free survival of 17.7 months in indolent lymphomas and 2.1 months in aggressive cohorts, highlighting varied outcomes.
  • The observational study included a diverse cohort of 107 patients with B-cell non-Hodgkin lymphoma across multiple centers, enhancing credibility.
  • Calls for further investigation to confirm long-term efficacy and safety in larger populations, addressing the trial-ineligible patients.

Cite This Study

Jallouk et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4d5https://doi.org/10.1182/blood-2025-4515
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma2025
  2. 2Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study2025 · 1 citations
  3. 3Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis2025 · 2 citations
  4. 4Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study2025
  5. 5Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial2025 · 1 citations